
Aerpio Pharmaceuticals, Inc. Market Cap 2011-2026 | ARPO
As of February 14, 2026 Aerpio Pharmaceuticals, Inc. has a market cap of $ 104 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 63.6 M | 26.4 M | 132 M | 108 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 26.4 M | 82.5 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
440 M | $ 14.81 | -0.34 % | $ 6.04 B | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 3.93 | 0.26 % | $ 335 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
87.8 M | $ 3.24 | 13.85 % | $ 182 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.79 | -7.27 % | $ 4.31 M | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.48 | -0.98 % | $ 8.37 B | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Biogen
BIIB
|
29.4 B | $ 195.63 | 0.06 % | $ 28.7 B | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 216.28 | -0.83 % | $ 5 B | ||
|
Bristol-Myers Squibb Company
BMY
|
122 B | $ 60.51 | 1.12 % | $ 123 B | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 106.24 | 0.45 % | $ 27.2 B | ||
|
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.41 | 1.81 % | $ 360 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 9.33 | 0.32 % | $ 1.51 B | ||
|
Amneal Pharmaceuticals
AMRX
|
1.83 B | $ 14.8 | 1.13 % | $ 4.57 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |